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Abstract
Physiological dysregulation may underlie aging and many chronic diseases, but is chal-
lenging to quantify because of the complexity of the underlying systems. Recently, we de-
scribed a measure of physiological dysregulation, DM, that uses statistical distance to
assess the degree to which an individual’s biomarker profile is normal versus aberrant.
However, the sensitivity of DM to details of the calculation method has not yet been sys-
tematically assessed. In particular, the number and choice of biomarkers and the defini-
tion of the reference population (RP, the population used to define a “normal” profile) may
be important. Here, we address this question by validating the method on 44 common
clinical biomarkers from three longitudinal cohort studies and one cross-sectional survey.
DMs calculated on different biomarker subsets show that while the signal of physiological
dysregulation increases with the number of biomarkers included, the value of additional
markers diminishes as more are added and inclusion of 10-15 is generally sufficient. As
long as enough markers are included, individual markers have little effect on the final met-
ric, and even DMs calculated from mutually exclusive groups of markers correlate with
each other at r~0.4-0.5. We also used data subsets to generate thousands of combina-
tions of study populations and RPs to address sensitivity to differences in age range, sex,
race, data set, sample size, and their interactions. Results were largely consistent (but
not identical) regardless of the choice of RP; however, the signal was generally clearer
with a younger and healthier RP, and RPs too different from the study population per-
formed poorly. Accordingly, biomarker and RP choice are not particularly important in
most cases, but caution should be used across very different populations or for fine-scale
analyses. Biologically, the lack of sensitivity to marker choice and better performance of
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Introduction
While the fundamental biological mechanisms of aging are not yet clear, an increasing number
of researchers are converging on the idea that aging is complex and multi-factorial [1,2], possi-
bly emerging from a dysregulation of the physiological regulatory networks that maintain
organismal homeostasis [3,4,5,6], also called allostatic load [7]. While this hypothesis is attrac-
tive, the complexity of the systems involved makes it hard to test it, and methods are needed to
measure the relative stability of the system. A few studies have applied sophisticated statistical
approaches with confirmatory but complex results [8,9,10,11,12]. The operationalization of
multi-system dysregulation and allostatic load remains a challenge for the field [7].
Recently, we proposed a method for measuring physiological dysregulation based on the
statistical distance (DM) among a set of biomarkers [13]. Statistical distance uses the correlation
structure of the biomarkers to measure how aberrant each individual’s profile is with respect to
the overall average (centroid) of the reference population. We hypothesized that individuals
with a more deviant overall biomarker profile were more dysregulated; we validated this inter-
pretation by demonstrating that DM increases with age within individuals and, after controlling
for age, predicts mortality, frailty onset, and chronic disease onset [13,14,15]. This is true de-
spite the fact that DM is often uncorrelated with its component biomarkers. Additionally, we
showed that this was true for many different combinations among a limited set of 14 biomark-
ers that the signal increased as more biomarkers were included, and that the biomarkers need
not be chosen based on specific a priori hypotheses regarding their role in aging. These find-
ings, if generalizable to other biomarkers and contexts, have important biological implications:
the ability to detect a similar signal with different combinations of markers, and to better detect
it with more markers (regardless of which), would suggest that dysregulation is a diffuse prop-
erty of overall system state rather than a function of a small number of physiological pathways.
However, two important aspects of validation remain to be completed. First, the signal of
DM is potentially confounded by or mixed with signals of dysregulation in particular systems
or by the effect of specific biomarkers. Therefore, to validate the use of DM for assessing general
physiological dysregulation, we must quantify how DM values calculated from many different
sets of biomarkers correlate, using a larger pool of biomarkers than our previous studies. If the
redundancy were very high, namely if DM values calculated based on different sets of biomark-
ers are highly correlated, it would indicate that physiological dysregulation could be measured
with virtually any set. On the other hand, if DM values are little or un-correlated, this would in-
dicate that physiological dysregulation is not approximated in the same way by different bio-
marker sets. In this case, increasing the number of biomarkers may be necessary to achieve a
better signal of a general physiological dysregulation at the organism level. Second, in order to
identify the degree to which a biomarker profile is deviant or aberrant, it is necessary to define
“normal.” This is achieved through use of a reference population (RP), based on which the
mean vector and variance-covariance structure of the variables is estimated. DM measures the
distance from this RP mean [16]. For most applications, DM is calculated using the entire sam-
ple available as the RP. However, when using DM as a measure of physiological dysregulation,
it is not clear that the entire sample is the appropriate RP: for example, perhaps it is best to se-
lect a young, healthy sub-population from the whole population in order to best estimate
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parameters associated with a state of “robust health.” However, increased sample size for the
RP should also be important to improve estimation of population parameters; if sample size is
sufficiently important, it might be preferable to use the entire population rather than to try to
choose healthy subsets. In turn, it might sometimes be advisable to use an outside population
that is younger and/or has a larger sample size as an RP, despite potential differences in the
population composition. Lastly, it is possible that population demographic composition (by
sex, race, etc.) could influence the appropriateness of a population as a reference.
Addressing the questions outlined above would provide confidence in the use of DM as a
measure of physiological dysregulation and concrete guidance as to how to use it. They also
could provide substantial biological insight into what physiological dysregulation is. For exam-
ple, if DM is highly robust to biomarker choice, it will suggest a diffuse signal of dysregulation
and imply that dysregulation is fully a system-level property of a complex system (i.e., an inte-
grated regulatory network). If demographic characteristics of RPs beyond age have little influ-
ence on the calculation of DM, this would imply that a healthy biomarker profile is very similar
under different demographic contexts.
To address these issues, we investigated the consistency of the physiological dysregulation
signal across DM values from different biomarker sets (overlapping and non-overlapping) and
numbers, by testing their correlations with each other and with age. We also performed a series
of sensitivity analyses [17] designed to test the robustness of the performance of DM when it is
calculated based on various RPs. We assessed the performance of different versions of DM
based on their correlations with each other and their ability to predict mortality, frailty, chronic
diseases, and changes with age within individuals. We replicated the analyses on data from
three longitudinal cohort studies and one cross-sectional survey.
Materials and Methods
Data Sets
InCHIANTI (Invecchiare in Chianti) is a prospective study with participants randomly select-
ed from two towns in the Chianti area in Italy (1156 adults aged 65–102 and 299 aged 20–64),
described in detail elsewhere [18]. Baseline visits occurred in 1998–2000 with follow-ups in
2001–2003, 2005–2006 and 2007–2008. WHAS (Women’s Health and Aging Study) is a set of
two complementary prospective studies of elderly women from Baltimore City and County in
Maryland, USA [19,20]. WHAS I included 1002 women aged65 among the one-third most
disabled in their community. WHAS II included 436 women aged 70–79 among the two-
thirds least disabled. Baseline visits occurred in 1992–95 and in 1994–96 for WHAS I and II,
respectively, with follow-up visits conducted 1.5, 3, 6, 7.5, and 9 years later. BLSA (Baltimore
Longitudinal Study of Aging) is longitudinal study of ageing that started in 1958 [21]. Partici-
pants were aged 21–96 and were largely middle- to upper-class, from the Baltimore and
Washington DC area, and were followed approximately every two years. The study design
was modified in 2003 whereby the number of biomarker measured increased substantially
[21]. For this study, we are thus using data collected since 2003. NHANES (National Health
and Nutrition Examination Survey) is a continuous cross-sectional stratified survey designed
to be representative of the US population. Data are updated approximately every year and are
made available freely (Centers for Disease Control and Prevention of the U.S. Department of
Health and Human Services; http://www.cdc.gov/nchs/nhanes.htm). We used data from the
waves 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, and 2009–2010, which
have been described in detail elsewhere [22].
All aspects of WHAS, InCHIANTI, and BLSA research were approved by the ethics com-
mittees at the institutions responsible for data collection, and this secondary analysis was
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approved by the ethics committee (Comité d’éthique de la recherche en santé chez l’humain) at
the Centre de recherche clinique du CHUS, project # 11–020. Participants signed informed con-
sent for data collection and analysis. Although the data used in these analyses cannot be freely
shared due to confidentiality constraints related to human medical data, they are all available
to researchers submitting an appropriate research proposal: WHAS at https://jhpeppercenter.
jhmi.edu/ec_proposal/login.aspx, InCHIANTI at http://www.inchiantistudy.net/obtain_data.
html, and BLSA at http://www.blsa.nih.gov/researchers.
Biomarker Selection
For analyses on the sensitivity of DM to which biomarkers are included, we selected 44 bio-
markers that were available in multiple studies with large sample sizes (>1,000 observations
per data set). Due to data availability, respectively one and nine markers were excluded from
WHAS and NHANES (Table 1). This resulted in a final list that was composed nearly exclu-
sively of markers that are commonly used in clinic. Fig 1 shows the mean values for each bio-
marker in NHANES and by subset, in relation to reported reference ranges (see S1 Table for
details and S1–S3 Figs for graphs for other data sets). In other data sets, mean values for some
biomarkers (e.g. lactate dehydrogenase, total cholesterol, glucose) lie outside reported ranges,
which is to be expected with an overrepresentation of older adults. The raw correlations be-
tween all biomarkers are shown in S4 through S7 Figs; overall, they are similar from one data-
base to the other (Figs were drawn with the corrplot package for R).
Mahalanobis Distance Calculation
Once combinations of biomarkers were selected (see below), DM was calculated as previously
described [13] using the mahalanobis function in R. For analyses on sensitivity of DM to
biomarker selection, we used all observations as the RP to compute μ (the vector of mean
biomarker values) and S (the variance-covariance matrix among the biomarkers). DM was
log-transformed for subsequent analyses. For analyses on RP, we distinguish the “study popu-
lation” (the individuals for whom we calculate DM), from the RP, the individuals based on
whom we calculate μ and S. For the three longitudinal studies (WHAS, InCHIANTI, BLSA),
we used all visits available for an individual, i.e. those for which we had measurements for all
biomarkers. Thus, one visit for one person equated to one observation. For NHANES only
one visit per individual was available. All statistical analyses were conducted in R v3.0.1 and
code is available upon request.
Analyses for Sensitivity of DM to Biomarker Composition
For analyses on sensitivity of DM to biomarker composition, the goal was to evaluate (a) the
optimal/minimum number of biomarkers to include in DM; (b) which biomarkers to include
or exclude, if there were major differences; and (c) the extent to which DM produces a robust
signal independent of biomarker composition, indicating that it detects a system-level proper-
ty. However, in order to evaluate the performance of different combinations of biomarkers,
we need something to compare them to. We chose to make two separate comparisons. First,
we compared the signal of one random combination to another random combination using
Pearson correlation coefficients. In this way, we could identify how best to measure a general
signal of DM, i.e. one that does not depend too much on what markers are included (see
below). Second, we used age as an external benchmark. Each of these analyses is described in
detail below.
Correlation among DMS calculated using random, mutually exclusive pairs of biomark-
ers. DM was generated using random, mutually exclusive combinations of biomarkers so as to
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Table 1. Biomarkers used in this study and number of observations for each data set.
Biomarkers BLSA WHAS InCHIANTI NHANES
A/G ratio 2975 2824 3637 n.a.
Albumin (serum) 2977 3736 3637 39828
Alkaline phosphatase 2977 3725 3640 39825
ALT 2963 3738 3648 39734
AST 2977 3737 3646 39732
Basophil % 2928 2566 3641 51193
BUN/creatinine ratio 2410 3734 3647 n.a.
Calcium 2977 3721 3637 39826
Cholesterol 2976 3030 3649 46625
Chloride 2977 3726 3638 39818
Serum creatinine 2977 3737 3651 n.a.
C-reactive protein 1349 2748 3627 47982
DHEAS 2061 2980 2991 n.a.
Eosinophil % 2954 2566 3641 n.a.
Estradiol 1908 2726 1927 n.a.
Ferritin 2965 2827 3617 25705
Folate (serum) 2943 2807 2166 49787
Free T4 2928 n.a. 1199 8630
GGT 2854 2826 3644 39823
Glucose 2969 3738 3648 16095
Hemoglobin 2953 3641 3643 51335
Hematocrit 2956 3641 3643 51335
HDL 2976 3267 3646 46619
IGF-1 2283 2784 2964 n.a.
IL-6 1342 2814 2974 n.a.
Iron 2881 2813 3637 39810
Potassium 2973 3720 3643 39823
LDH 2948 2810 3634 39730
Lymphocyte % 2955 2566 3641 51193
MCH 2953 3641 3643 51335
MCHC 2953 3641 3643 51335
Magnesium 2973 2778 3635 n.a.
Monocyte % 2954 2566 3641 51193
Neutrophil % 2955 2565 3642 51193
Platelets 2954 3620 3643 42535
Red blood cell count 2928 3641 3643 42536
RDW 2926 3640 3643 51335
Sodium 2977 3726 3644 39825
Total protein 2951 3739 3641 39789
Triglycerides 2947 3029 3649 21000
TSH 2927 2998 1153 4392
Uric acid 2944 2823 3625 39822
Vitamin B12 2940 2803 2166 32776
White blood cells 2930 3641 3643 51332
doi:10.1371/journal.pone.0122541.t001
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be able to study how the number of biomarkers included (Nbm) and the identity of the biomark-
ers included influenced the stability of theDM signal. It was not computationally feasible to
study all possible biomarker combinations (reaching a maximum of 1019 possibilities with 15
biomarkers per group), so for each Nbm in 2 Nbm 22 we generated 5000 random combina-
tions by sampling the 44 markers without replacement. In each case (5000 × 21 levels of Nbm),
we then generated a paired, non-overlapping combination containing the same number of
Fig 1. Mean biomarker values for NHANES in relation to reported reference ranges.Mean values for each biomarker were normalized according to the
reported minimal and maximal normal values, represented by the vertical lines. For biomarker with only one specified normal value, the other vertical line
represents minimal or maximal value for the data set (see S1 Table for details). Graphs for other data sets can be found in S1–S3 Figs.
doi:10.1371/journal.pone.0122541.g001
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markers selected from among those not included in the initial combination. This allowed us to
compare the performance of different versions of DM where the biomarkers are mutually exclu-
sive but Nbm is equal. In particular, we could assess how strongly alternative versions of DM cor-
related with each other, removing any redundancy due to shared biomarker composition. Note
that, while it was essential that paired combinations be mutually exclusive, this restricted the
maximum Nbm to 22 of the 44 markers. Also, since we were more interested in the distribution
of correlations than in testing the significance of each one, we did not control for the non-inde-
pendence of observations coming from the same individuals. However, we repeated the analyses
using a single randomly selected visit per individual to insure that non-independence did not
bias our conclusions in analyses using all observations.
By storing the information about which biomarkers were in each combination, we could as-
sess the association between the 5000 × 21 correlation coefficients and whether or not each
marker was included in one of the two groups, as well as between the correlation coefficient
and Nbm. To do this, we ran linear regression to examine the association between the correla-
tion coefficient (the dependent variable) and either Nbm or the presence/absence of each bio-
marker in the combination (the independent variable(s)). While we do not interpret each
correlation in terms of significance (as aforementioned), we used the p-values of the Pearson
correlation to filter out “insignificant” correlations (p>0.05) in order to reduce the noise for
the linear regressions, as low correlations are more likely to be truly insignificant, hence non-
informative about the effect of a given biomarker.
Association between age and DMS calculated using random biomarker combinations.
In order to assess how Nbm and biomarker choice affected the association between DM and
age, we used 5000 random combinations of biomarkers for each Nbm in 2 Nbm 44, this
time without pairing or mutual exclusivity. The relationship of DM with age is non-linear,
and in particular there are conflicting effects of within-individual increases with age and
higher mortality rates among individuals with higher DM [13,15]. Accordingly, the correla-
tion of DM with age is not very informative, and a more sophisticated measure of association
was needed. Hence, for each combination (5000 × 43 levels of Nbm) we regressed log-trans-
formed, standardized, DM values on age by fitting linear and quadratic age terms, and ex-
tracted the multiple R-squared from the model, generating a measure of the variance in age
explained by DM. In this way, we could use linear regression to examine the association be-
tween the multiple R-squared (the dependent variable, a measure of the association between
DM and age) and either Nbm or the presence/absence of each biomarker in the combination
(the independent variable(s)).
Analyses for Sensitivity of DM to RP Characteristics
For sensitivity analyses on RPs, we used 12 biomarkers that were selected for our original study
[13] as results from the biomarker choice analyses suggested that inclusion of 10–15 markers
is generally sufficient for a good signal. The markers used were hemoglobin, hematocrit,
red blood cell counts (RBC), sodium, calcium, potassium, chloride, cholesterol, creatinine, the
blood-urea nitrogen (BUN) to creatinine ratio, albumin, and basophil percentage among white
blood cells. The BLSA data set was not used for analyses on RPs due to (a) the lack of outcome
data such as in WHAS and InCHIANTI, and (b) the lack of a large population of younger
adults, such as in NHANES.
To evaluate the effect of different RPs, DM was analysed in relation to age, mortality, frailty,
cardiovascular disease (CVD) and number of comorbidities, with RPs that produce stronger
associations with these variables presumed to be “better.” NHANES has no longitudinal data
so only the correlation between DM and age is presented. For InCHIANTI and WHAS,
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individual changes in log-DM with age were modelled using linear regression models for each
individual to estimate his/her slope; weighted t-tests were then used to assess whether the
slope was significantly different from zero, weighted by the number of observations per indi-
vidual. This method, while theoretically slightly inferior to a full multi-level model, was much
more computationally feasible for the large number of analyses we were running. The rela-
tionship between DM and subsequent mortality was modelled using Cox proportional hazards
models (coxph function, survival package), controlling for a spline of age. Frailty was mea-
sured as the number of Fried’s frailty criteria present (0–5) and assessed using linear regres-
sion controlling for age, as was number of comorbidities [23]. CVD was assessed using
regression controlling for age, but differently in WHAS and InCHIANTI based on data con-
straints (see S1 Text for details).
The above analyses were run for a large variety of combinations of RP and study population.
The key parameters that were varied were (a) data set; (b) sample size of 50, 100, 200, 300 or
full population, using random sub-samples (only pertinent for the RP); (c) age range (only ap-
plied to the RP); (d) sex (NHANES and InCHIANTI only); and (e) race (WHAS only). Each
parameter combination could be applied to either the study population or the RP; for example,
we could examine the performance of RP that was from NHANES, sample size 200, aged
20–40, male, and black for calculating values in a study population that was from InCHIANTI,
aged 65+, and female. However, the number of possible such combinations far exceeded our
analytical capacity; accordingly, we manually chose the most pertinent combinations, generally
assessing one parameter “axis” at a time, and occasionally looking at their interactions. Each
sensitivity analysis for a given RP-study population pair was conducted in replicate on 100 ran-
domly chosen combinations among the 4095 possible combinations of the 12 biomarkers.
Each sensitivity analysis is thus expressed as a summary of the predictive power across the 100
combinations, as described below.
In addition, we performed a series of meta-regressions to test the importance of RP charac-
teristics across the many different RP-study population combinations modelled. For each com-
bination of RP-study population-outcome, we calculated the percentage of the 100 models (i.e.,
100 biomarker combinations) that was significant at α = 0.05. This percentage was used as the
dependent variable in meta-regressions, and the independent variables were various combina-
tions of health outcome (age slope, mortality, frailty, etc.) and RP or study population traits
such as sex, age, race, their interactions, etc. as appropriate.
Graphical representation of RP results. Because of the large number of analyses to be pre-
sented, we developed a graphical summary method using matrices of filled, shaded rectangles.
Each rectangle simultaneously summarizes the effect size, p-value, and percent of significant p-
values (at α = 0.05) among the 100 analyses. The percentage of significant p-values is represented
by the height of shading within the rectangle: white represents no significant result, all shaded
indicates that all 100 analyses were significant. The colour of the shading represents the direction
of the effect (blue is a positive effect, red a negative effect), and the hue represents the average p-
value among the significant p-values, with darker hues indicating lower p-values (greater signifi-
cance). Each matrix of rectangles has a row for each possible outcome (age, mortality, CVD,
etc.) and a column for each different RP. The leftmost column is a “reference RP,” i.e., a relatively
straightforward choice, such as using the entire study population as its own RP. The other col-
umns are compared to this choice, with the width of the rectangle representing the average effect
size among significant analyses, relative to the effect size of the rectangle in the leftmost column
and the same row. Wider rectangles indicate larger effect sizes. Accordingly, all rectangles in the
leftmost column have the same width, and the width of other rectangles can only be compared
to rectangles in the same row. While the details of the interpretation of these Figs are thus com-
plex, the visual result is simple: more and darker blue means better performance.
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Results
Pairwise DM Correlations and Predictive Value of Age for Different Sets
of Biomarkers
The correlation between pairs of DM was always positive and increased with the number of bio-
markers per group. The patterns obtained for the different data sets were remarkably similar:
approaching 20 markers per group, the correlation starts to level off at around 0.4 in all four
data sets, with limited variation around the mean as shown by the 2.5 to 97.5 percentiles of ob-
served correlation coefficients (Fig 2). However, whether a plateau truly occurs at around 20
biomarkers is not clear since our study did not go beyond 22 biomarkers per group (half of the
44 available, to preserve mutual exclusivity). The results obtained with the full data sets vs. the
Fig 2. Mean correlation between pairwiseDM values as a function of biomarker number.Grey vertical bars indicate 2.5 to 97.5 percentiles of observed
correlation coefficients calculated between ~5,000 randommutually exclusive pairs generated from a pool of 44 markers.
doi:10.1371/journal.pone.0122541.g002
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data sets restricted to one visit per individual were similar (not shown). Therefore, hereafter we
only present the results for the former.
The relationship between DM and age is somewhat less stable across data sets than the cor-
relations. Overall, the variance explained by quadratic regressions of predicted DM with age
tends to increase when more biomarkers are included in DM calculation, but reaches a plateau
at around 30 biomarkers (Fig 3). Note that we could show all 44 markers in Fig 3 because we
were not constrained to use mutually exclusive groups, as in Fig 2. This global pattern is true
for BLSA, InCHIANTI and WHAS but not NHANES, which is the only cross-sectional
study. The larger error bars indicate greater heterogeneity in variance explained across
biomarker combinations.
Fig 3. Mean variance of predictedDM values with age as a function of biomarker number.Grey vertical bars indicate 2.5 to 97.5 percentiles of observed
variances in age explained by DM calculated from ~5,000 random combinations generated from a pool of 44 markers.
doi:10.1371/journal.pone.0122541.g003
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Contribution of Individual Biomarkers to pairwise DM Correlations and
Relation to Age
Individual biomarkers contributed in diverse ways to the correlation between DM values, fol-
lowing three major patterns: those with a positive effect, i.e. increasing the strength of the cor-
relation; those with a negative effect, i.e. decreasing the strength of the correlation; those with
no clear effect in either direction. Selected examples of biomarkers showing these three patterns
are illustrated in Fig 4 and graphs for all biomarkers can be found in S8–S11 Figs. Two patterns
emerge from this analysis. First, whether positive or negative, the effect of a marker on the
strength of the correlation decays with increasing Nbm and typically becomes negligible at high-
est Nbm values. Second, the effect of specific markers is quite consistent from one data set to the
other (Fig 4, S8–S11 Figs): markers that have a strong positive (e.g. hemoglobin, MCH, neutro-
phils) or negative (e.g. basophil, folate, vitamin B12) effect tend do so in all data sets, while
those having a weak effect in one set tend to have either a similar or non-significant effect in
other sets (e.g., HDL, iron, sodium). Notably, several blood markers follow the same pattern,
with a strong positive effects on the strength of the correlation that declines sharply with in-
creasing Nbm (hemoglobin, haematocrit, RBC and to a lesser extent red blood cell width;
RDW). A few markers depart from these general rules. For example, alanine aminotransferase,
estradiol and free thyroxine (T4) clearly show a positive effect on the correlation in some data
sets and a negative effect in others (S8–S11 Figs).
The effects of including individual biomarkers on the association of DM with age were much
less clear. Several examples are shown in Fig 5, with full results in S12–S15 Figs. Results differed
across data sets in most cases, often dramatically. For example, CRP has a large positive effect in
BLSA, an effect that goes from clearly negative to clearly positive as Nbm increases in WHAS,
and no major effect in InCHIANTI. The smaller y-axis scale for WHAS is probably due to less
variance in age explained by DM in this data set due to the smaller age range of participants. For
correlations, the effect of individual markers consistently decreased as Nbm increased, but for
the association of DM with age, many patterns were observed: stable positive effects, stable nega-
tive effects, effects that go from negative to positive and vice-versa, effects that are non-linearly
associated with Nbm such that intermediate values of Nbm are either higher or lower than ex-
treme values, etc. In short, the inclusion or exclusion of individual variables in DM appears to be
much more important for its association with age than for correlations among alternative ver-
sions of DM. However, the details of these effects appear to depend on many other factors.
Sensitivity of DM Analyses to RP Choice
There was a clear tendency for better performance using younger RPs, especially for a positive
slope of DM with age (Fig 6 and S16 Fig). For example, in a regression analysis looking only at
InCHIANTI as both RP and study population, using an RP of patients aged 20–50 or 20–70 (as
opposed to the whole population) improved model performance substantially (12% and 16%,
p = 0.03 and 0.0004, respectively; Fig 6). Likewise, the use of healthier RPs (i.e., not dying or
without comorbidities) for InCHIANTI clearly increased the average effect size and p-value for
the slope of DM with age, compared to the full data set (Fig 7). The only exception was the
slope of DM with age for those not dying during follow-up, probably due to a difference in the
age composition of the two sub-populations. On the other hand, there was essentially no effect
of sample size on the results (Fig 8). This was true in InCHIANTI, WHAS, and NHANES, both
visually and using regression analyses. Sample size was never a significant explanatory variable
in regression models.
The effects of population choice, as well as sex and race, are less clear but tend to demon-
strate some sensitivity of model performance to RP variation (Fig 9 and S17–S19 Figs). The
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Fig 4. Contribution of selected individual biomarkers to pairwiseDM correlations, as a function of biomarker number. The X-axis represents the
number of biomarkers per group (Nbm) and the Y-axis reports the coefficient (β) from a linear regression of the DM pairwise correlations onNbm. βs represent
the deviation from the average correlation when a given biomarker is included in the calculation of DM; positive values thus indicate improved performance of
DM, and negative values decreased performance. Colors indicate the magnitude of p-values, with darker red being more significant and white not significant.
Graphs for all biomarkers can be found in S8–S11 Figs.
doi:10.1371/journal.pone.0122541.g004
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number of significant models among the 100 varied substantially depending on which data set
was used for the RP and the study population. For example, WHAS performed substantially
worse as its own RP (22% worse than InCHIANTI, p<0.0001; Fig 9), whereas using
InCHIANTI as the study population, there was a substantial decrease in performance using
WHAS or NHANES as RP, rather than InCHIANTI itself (-10% and -5%, p = 0.04 and 0.01, re-
spectively; S17 Fig). Likewise, results were often markedly different using black, white, and
mixed RPs in WHAS (S18 Fig). Qualitatively, conclusions went in the same direction, but the
number of significant models, significance level, and effect size often differed substantially.
Strangely, there were often opposing effects for effect size and significance, perhaps suggesting
that results obtained for race are an artefact and should not be over-interpreted.
Fig 5. Contribution of selected individual biomarkers to change in variance in age explained byDM. The X-axis represents the number of biomarkers
per group (Nbm), while the Y-axis reports the change in howmuch variance in age is predicted by DM with the inclusion of the given biomarker, based on a
meta-regression of all the R-squareds calculated for individual quadratic regressions of age and DM. Colors indicate the magnitude of p-values, with darker
red being more significant and white not significant. Graphs for all biomarkers can be found in S12–S15 Figs.
doi:10.1371/journal.pone.0122541.g005
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The sex of the RP and study population generally produced modest but significant effects on
the results, based largely on analyses within InCHIANTI (S19 Fig). As with most analyses above,
use of a different RP never changed overall conclusions, but the number of significant models
and effect sizes varied a bit. Unlike for race, variation in number of significant models, signifi-
cance level, and effect size were consistent with each other. The more consistent results than for
race suggest that the sex composition of the RP may have real if modest effects on results.
Discussion
This study assessed the sensitivity of DM to biomarker choice and demographic composition of
the RP, with the dual goals of establishing a standard methodology to calculate DM and under-
standing the biological implications of its stability profile. Overall, we found that performance
of DM as a marker of physiological dysregulation increases with the inclusion of more
Fig 6. Effects of RP age intervals on prediction of age and health outcomes. The study population represented here is the full InCHIANTI data set with
InCHIANTI RPs covering different age intervals. The width of the rectangle represents the average effect size among significant analyses, relative to the
effect size of the rectangle in the leftmost column (entire study population as its own RP). The percentage of significant p-values is represented by the height
of shading within the rectangle, the shading colour represents the direction of the effect (blue is a positive effect), and the hue represents the average p-value
among the significant p-values, with darker hues indicating lower p-values.
doi:10.1371/journal.pone.0122541.g006
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biomarkers, but that there are diminishing returns at higher numbers of markers, and that
10–15 markers is generally sufficient to recover a strong signal. The choice of markers has rela-
tively little effect on the correlations between different versions of DM, but can be important in
more specific applications, such as measuring the strength of the association between DM and
age. However, which biomarkers improve DM signal appears to be context-dependent, making
it difficult to generate a list of preferred markers without a more extensive analysis across dif-
ferent populations. The effect of RP choice was also of moderate importance in some contexts:
it appears generally better to use a younger and healthier RP, and one that is otherwise demo-
graphically similar to the study population. However, RP sample size does not matter much
beyond 50.
These results are nuanced and complex rather than black-and-white, so we work through
some of these details below; the overall take-home messages are: (a) We confirmed a general
Fig 7. Effects of RPs’ survival and health status on prediction of age and health outcomes. The study population represented here is the full
InCHIANTI data set with InCHIANTI RPs defined according to survival and health status. The width of the rectangle represents the average effect size among
significant analyses, relative to the effect size of the rectangle in the leftmost column (entire study population as its own RP). The percentage of significant p-
values is represented by the height of shading within the rectangle, the shading colour represents the direction of the effect (blue is a positive effect), and the
hue represents the average p-value among the significant p-values, with darker hues indicating lower p-values.
doi:10.1371/journal.pone.0122541.g007
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insensitivity of DM to biomarker choice across 44 markers (compared to the 14 previously ana-
lysed), strengthening the conclusion that physiological dysregulation is an emergent property
of system state not particularly linked to any single molecule, pathway, or physiological system.
(b) A modest sensitivity of DM to RP choice suggests that there is not a single universal optimal
physiological state across populations, but that any differences are modest. (c) For most studies
for most purposes, choice of biomarkers and RP will not have major impacts on the results as
long as 10–15 relatively diverse markers are chosen and the RP is not too different from the
study population. However, studies making fine-scale inferences should use caution and at-
tempt to validate these choices.
Having a robust, simple, effective measure of physiological dysregulation would represent
a major step in a number of fields. Dysregulation could serve as a proxy for individual health
status in large-scale population surveys in fields such as demography, economics, and sociolo-
gy, and may represent a substantial improvement over self-reported health, single-biomarker
Fig 8. Effects of RP sample size on prediction of age and health outcomes. The study population represented here are individuals aged 20–70 from the
InCHIANTI data set with RPs of various sample sizes drawn randomly from the study population. The width of the rectangle represents the average effect
size among significant analyses, relative to the effect size of the rectangle in the leftmost column (entire study population as its own RP). The percentage of
significant p-values is represented by the height of shading within the rectangle, the shading colour represents the direction of the effect (blue is a positive
effect), and the hue represents the average p-value among the significant p-values, with darker hues indicating lower p-values.
doi:10.1371/journal.pone.0122541.g008
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measures, or summed indices of criteria [24,25,26,27,28]. Clinically, a marker of dysregulation
may improve on single biomarkers in certain contexts. For example, it may help predict im-
pending frailty [15] or serve as a physiotype for frailty. In aging studies, dysregulation may
serve as an approximation of biological age [29]. We recently showed that DM works as a mea-
sure of body condition in wild animals [30], suggesting major applications in ecology as well,
where existing measures of body condition have been criticized [31]. In studies using lab ani-
mals, DMmay serve as a simple measure of health status. In clinical trials, lack of ability to mea-
sure long-term outcomes is a major problem; DM could be added to such trials as a secondary
outcome to predict long-term benefits or harms of medications or other treatments. The impli-
cations of a robust measure of physiological dysregulation are thus wide-ranging.
Fig 9. Effects of RP drawn from external young populations on prediction of age and health outcomes. The study population represented here is the
full WHAS data set with young RPs from each of the three data sets as indicated. The width of the rectangle represents the average effect size among
significant analyses, relative to the effect size of the rectangle in the leftmost column (entire study population as its own RP). The percentage of significant p-
values is represented by the height of shading within the rectangle, the shading colour represents the direction of the effect (blue is a positive effect), and the
hue represents the average p-value among the significant p-values, with darker hues indicating lower p-values.
doi:10.1371/journal.pone.0122541.g009
Validating Statistical Distance as Physiological Dysregulation
PLOS ONE | DOI:10.1371/journal.pone.0122541 April 13, 2015 17 / 25
Biological implications
The better performance of younger and healthier RPs confirms a prediction and thus supports
the interpretation of DM as a measure of physiological dysregulation. Including sicker or older
individuals in the RP will pull the RP mean away from an ideally healthy state to the extent
that there are general differences in biomarker levels between young and old, healthy and sick.
If DM truly measures dysregulation, it is thus expected that distance from the mean of young,
healthy individuals will provide a stronger signal than distance from the overall mean. The lack
of strong sensitivity to sample size, sex, and data set confirms the idea of a generalized underly-
ing signal, supporting the hypothesis of dysregulation and concordant with studies on allostatic
load and aging [9,10,11,32,33,34,35]. On the other hand, the occasional sensitivity to RP pa-
rameter combinations and the effects of some biomarkers on the association between DM and
age suggests that physiological dysregulation does not proceed in a completely uniform fashion
such that all biomarkers measure it interchangeably in all populations; likely there is some het-
erogeneity in dysregulation processes across biological sub-systems, in ways that may differ
across populations.
An interesting parallel with our findings is a common measure of clinical frailty, the frailty
index (FI). The FI is based on the accumulation of deficits during aging, and is expressed as a
percentage of deficits observed among those assessed [36,37,38]. As with DM, FI shows mini-
mal sensitivity to the choice of deficits, though the signal increases asymptotically as more
deficits are added to the measure [39]. It would thus appear that both clinical deficits and bio-
marker dysregulation follow a similar pattern of detecting an underlying signal that is physio-
logically generalizable. We hypothesize that DMmay be a physiological equivalent to FI, and a
precursor to other frailty measures such as Fried’s frailty phenotype [23]. Indeed, a recent
study on biomarkers and FI shows that their inclusion in FI is highly concordant with a general
FI signal [40]. The relationship between DM and FI will be explored in future studies.
Detailed methodological considerations
One of our more puzzling results was the important but inconsistent effects of biomarker
choice on association with age. For example, why would including estradiol in DM strengthen
the association with age in BLSA, decrease it in WHAS, and improve it in InCHIANTI for
small numbers of biomarkers but decrease it for large numbers of biomarkers (Fig 5)? There
are probably two key answers to such questions. First, the demographics of the population are
quite important. Our study populations differ markedly in composition by age, sex, race, and
socio-economic status. It is evident that the small variance in age explained by DM in WHAS is
due to the limited age-range in that study. How estradiol affects the association of DM with age
in WHAS is a function of how it changes between ages ~65–90 in women, whereas how it af-
fects the association of DM with age in other populations depends also on its changes in men,
and in younger women (i.e., pre-menopausal). Estradiol is an extreme example in this case,
with major known differences in levels and changes between men and women, and pre-vs.
post-menopause in women. Second, there are likely interactions with the other markers pres-
ent. Two redundant markers that improve the association of DM with age may each be quite
important with smaller numbers of markers, but may decrease in importance with larger num-
bers of markers, as the probability increases for the other to be included.
As for the sensitivity of DM analyses to RP choice, the results presented here simultaneously
provide a clear and a complex picture. Generally speaking, most conclusions are unlikely to
change as a function of RP choice. There was minimal sensitivity to sample size, indicating that
50 observations provide a robust estimate of the variance-covariance matrix. Unsurprisingly,
the use of a younger or healthier RP significantly improved the model performance. At the
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same time, the details provide a much more complex picture. For instance, mixed results were
obtained when the RP came from a different data set on a different continent. The different
demographic characteristics between data sets make it hard to evaluate if this was due to demo-
graphic aspects versus other more specific population traits such as population-specific physio-
logical profiles. In particular, the fact that WHAS contains only women 65 years and older
made it impossible to compare the use of a young, two-gendered WHAS population as a refer-
ence. Also, small differences were observed depending on the sex of the RP and study popula-
tion, but these effects were minor in terms of overall conclusions.
In contrast, using RPs that were racially distinct had a major impact on the results in
WHAS, the only data set in which we could perform this analysis. We do not believe this find-
ing is attributable to racially fixed differences in underlying biology, but rather due to several
more subtle factors. Blacks in WHAS are different from whites along a number of sociological
and health measures, and sample size was somewhat limited. Moreover, we did not find that
each race was its own best RP, but rather that findings changed unpredictably as the race of the
RP changed. Additionally, results were inconsistent across various measures of performance.
Accordingly, what we are seeing appears to be noise in the data and fine-scale complexity, and
we do not expect our results to be generalizable to the effect of race on RP performance in
other populations. For precisely this reason, our race results serve as an important caution in
terms of the general applicability of one RP to any other: while most of our results are relatively
robust to differences in RP, it is clearly possible to choose RPs that lead to different overall con-
clusions, and not always easy to predict exactly what these differences will be.
The only clear finding here that would indicate that it is best to use an RP that is different
than the study population is that younger and healthier RPs generally perform better. However,
it would not appear to be wise to use an RP of young individuals that is too different in other
ways (race, sex, country, etc.) from the study population, as indicated by the complex interactions
observed. The difference between a young population and the full population is clear but modest,
and when a young RP is not available from within the study population we would recommend
using the full study population as the RP rather than choosing an external young population.
Interacting with this, there was often a contrast in results for predictions of age versus health
outcomes in depending on RP. This difference could reflect the fact that many age-related
changes in physiology may be adaptive and protective, given other changes. Older individuals
may thus differ in their biomarker profiles from young individuals in some ways that are path-
ological and other ways that are adaptive. Whether it is best to use a younger reference popula-
tion may thus depend on a study’s context, particularly on the extent to which it may reflect
adaptive versus pathological changes with aging.
The most difficult question likely to arise in practice is what RP to choose for a small study
that cannot provide its own. If the study population is broadly representative of the population
at large, it might be feasible to choose a subsample from NHANES (which is publicly available)
as RP, but this appears not to be advisable if the study population has any particularities, as
they might make such an inference problematic. Luckily, the lack of sensitivity to sample size
suggests that even many small studies (50+ participants) may be able to provide their own RPs.
While the differences based on RP presented here are mostly minor, the importance of these
minor differences depends on context. If we simply wish to show that DM significantly predicts
health outcomes, choice of RP is not important. In contrast, we have observed J-shaped trajecto-
ries ofDM with age as opposed to the monotonic increases we would predict [15], and we believe
the left tail of the J-shape is due to an imperfect estimation of μ, the vector of mean biomarker
values. This suggests a more general limit of this study: we are estimating the “optimal” combi-
nation of biomarkers based on the mean combination. These two are likely close but not identi-
cal, and further work remains to find ways to better estimate optimal μ rather than mean μ.
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Conclusions
This study provides support for the biological interpretation of DM as physiological dysregula-
tion (via the better performance of younger, healthier RPs, as predicted) and for the interpreta-
tion of physiological dysregulation as an emergent property reflecting the state of complex
regulatory networks (via the relative insensitivity of DM to biomarker choice, and its improving
performance with inclusion of more biomarkers). In combination with previous studies, the fol-
lowing key predictions forDM have now been confirmed: (a)DM increases with age within indi-
viduals [13,14,15]; (b)DM predicts mortality, frailty, and chronic diseases independently of age
[15]; (c)DM functions similarly in different human populations and even in birds [14,15,30]; (d)
DM is relatively insensitive to which biomarkers are included [13,14,15]; (e) predictive power of
DM improves with the number of biomarkers included [13,14,30]; and (f) predictive power
ofDM improves when a younger, healthier RP is used. Given the sum of this evidence, we believe
that generalized use of DM as a measure of physiological dysregulation is now justified across a
wide range of contexts, including clinically, in studies of population health, in studies of aging,
and as a measure of body condition in an ecological context. The details of the results of this
study suggest that in most contexts, DM can be applied without detailed consideration of bio-
marker choice or of definition of the RP. However, for small sample sizes or highly specific and
particular study populations, we recommend that researchers perform sensitivity analyses to
confirm that results do not depend heavily on the choice of RP, and we recommend caution
over-interpreting fine-scale changes inDM, particularly in the lower part of its range, until more
robust methods of defining an optimal biomarker profile are identified.
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S1 Text. Supporting Materials and Methods. Particularly includes details of measures of
health status
(DOCX)
S1 Table. Biomarkers used, their mean values by data set, and reference ranges
(XLSX)
S1 Fig. Mean biomarkers values for BLSA in relation to reported reference ranges.Mean
values for each biomarker were normalized according to the reported minimal and maximal
normal values, represented by the vertical lines. For biomarker with only one specified normal
value, the other vertical line represents minimal or maximal value for the data set (see S1 Table
for details).
(TIF)
S2 Fig. Mean biomarkers values for WHAS in relation to reported reference ranges.Mean
values for each biomarker were normalized according to the reported minimal and maximal
normal values, represented by the vertical lines. For biomarker with only one specified normal
value, the other vertical line represents minimal or maximal value for the data set (see S1 Table
for details).
(TIF)
S3 Fig. Mean biomarkers values for InCHIANTI in relation to reported reference ranges.
Mean values for each biomarker were normalized according to the reported minimal and maxi-
mal normal values, represented by the vertical lines. For biomarker with only one specified nor-
mal value, the other vertical line represents minimal or maximal value for the data set (see S1
Table for details).
(TIF)
Validating Statistical Distance as Physiological Dysregulation
PLOS ONE | DOI:10.1371/journal.pone.0122541 April 13, 2015 20 / 25
S4 Fig. Correlation between biomarkers in the BLSA data. The magnitude of the correlation
between two markers is indicated by the color (scale on the right) and the width of the ellipse
shown (a narrow ellipse indicating a stronger correlation), while the tilt shows the sign.
(TIF)
S5 Fig. Correlation between biomarkers in the WHAS data. The magnitude of the correla-
tion between two markers is indicated by the color (scale on the right) and the width of the el-
lipse shown (a narrow ellipse indicating a stronger correlation), while the tilt shows the sign.
(TIF)
S6 Fig. Correlation between biomarkers in the InCHIANTI data. The magnitude of the cor-
relation between two markers is indicated by the color (scale on the right) and the width of the
ellipse shown (a narrow ellipse indicating a stronger correlation), while the tilt shows the sign.
(TIF)
S7 Fig. Correlation between biomarkers in the NHANES data. The magnitude of the correla-
tion between two markers is indicated by the color (scale on the right) and the width of the el-
lipse shown (a narrow ellipse indicating a stronger correlation), while the tilt shows the sign.
(TIF)
S8 Fig. Contribution of individual biomarkers to pairwise DM correlation for the BLSA
dataset. The X-axis represents the number of biomarkers per group (Nbm) and the Y-axis re-
ports the coefficient (β) from a linear regression of the DM pairwise correlations on Nbm. βs rep-
resent the deviation from the average correlation when a given biomarker is included in the
calculation of DM; positive values thus indicate improved performance of DM, and negative val-
ues decreased performance. Colors indicate the magnitude of p-values, with darker red being
more significant and white not significant.
(TIF)
S9 Fig. Contribution of individual biomarkers to pairwise DM correlation for the WHAS
dataset. The X-axis represents the number of biomarkers per group (Nbm) and the Y-axis re-
ports the coefficient (β) from a linear regression of the DM pairwise correlations on Nbm. βs rep-
resent the deviation from the average correlation when a given biomarker is included in the
calculation of DM; positive values thus indicate improved performance of DM, and negative val-
ues decreased performance. Colors indicate the magnitude of p-values, with darker red being
more significant and white not significant. Empty panels are shown for biomarkers with no
data for this particular data set (see text and Table 1 for details).
(TIF)
S10 Fig. Contribution of individual biomarkers to pairwise DM correlation for the
InCHIANTI dataset. The X-axis represents the number of biomarkers per group (Nbm) and
the Y-axis reports the coefficient (β) from a linear regression of the DM pairwise correlations
on Nbm. βs represent the deviation from the average correlation when a given biomarker is in-
cluded in the calculation of DM; positive values thus indicate improved performance of DM,
and negative values decreased performance. Colors indicate the magnitude of p-values, with
darker red being more significant and white not significant.
(TIF)
S11 Fig. Contribution of individual biomarkers to pairwise DM correlation for the
NHANES dataset. The X-axis represents the number of biomarkers per group (Nbm) and the
Y-axis reports the coefficient (β) from a linear regression of the DM pairwise correlations on
Nbm. βs represent the deviation from the average correlation when a given biomarker is
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included in the calculation of DM; positive values thus indicate improved performance of DM,
and negative values decreased performance. Colors indicate the magnitude of p-values, with
darker red being more significant and white not significant. Empty panels are shown for bio-
markers with no data for this particular data set (see text and Table 1 for details).
(TIF)
S12 Fig. Contribution of individual biomarkers to change in variance in age explained by
DM, for the BLSA dataset. The X-axis represents the number of biomarkers per group (Nbm),
while the Y-axis reports the change in how much variance in age is predicted by DM with the
inclusion of the given biomarker, based on a meta-regression of all the R-squareds calculated
for individual quadratic regressions of age and DM. Colors indicate the magnitude of p-values,
with darker red being more significant and white not significant.
(TIF)
S13 Fig. Contribution of individual biomarkers to change in variance in age explained by
DM, for the WHAS dataset. The X-axis represents the number of biomarkers per group (Nbm),
while the Y-axis reports the change in how much variance in age is predicted by DM with the
inclusion of the given biomarker, based on a meta-regression of all the R-squareds calculated
for individual quadratic regressions of age and DM. Colors indicate the magnitude of p-values,
with darker red being more significant and white not significant. Empty panels are shown for
biomarkers with no data for this particular data set (see text and Table 1 for details).
(TIF)
S14 Fig. Contribution of individual biomarkers to change in variance in age explained by
DM, for the InCHIANTI dataset. The X-axis represents the number of biomarkers per group
(Nbm), while the Y-axis reports the change in how much variance in age is predicted by DM
with the inclusion of the given biomarker, based on a meta-regression of all the R-squareds cal-
culated for individual quadratic regressions of age and DM. Colors indicate the magnitude of
p-values, with darker red being more significant and white not significant.
(TIF)
S15 Fig. Contribution of individual biomarkers to change in variance in age explained by
DM, for the NHANES dataset. The X-axis represents the number of biomarkers per group
(Nbm), while the Y-axis reports the change in how much variance in age is predicted by DM
with the inclusion of the given biomarker, based on a meta-regression of all the R-squareds
calculated for individual quadratic regressions of age and DM. Colors indicate the magnitude
of p-values, with darker red being more significant and white not significant. Empty panels
are shown for biomarkers with no data for this particular data set (see text and Table 1
for details).
(TIF)
S16 Fig. Effects of RPs age intervals on prediction of age and health outcomes. The study
population represented here is the full NHANES data set stratified by sex as indicated, with
RPs of differing age intervals (also NHANES). The width of the rectangle represents the aver-
age effect size (here the correlation between DM and age) among significant analyses, relative to
the effect size of the rectangle in the leftmost column (entire study population as its own RP).
The percentage of significant p-values is represented by the height of shading within the rect-
angle, the shading colour represents the direction of the effect (blue is a positive effect), and the
hue represents the average p-value among the significant p-values, with darker hues indicating
lower p-values.
(TIF)
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S17 Fig. Effects of RPs drawn from external young populations on prediction of age and
health outcomes. The study population represented here is the full InCHIANTI data set with
RPs of young individuals from each of the three data sets. The width of the rectangle represents
the average effect size among significant analyses, relative to the effect size of the rectangle in
the leftmost column (entire study population as its own RP). The percentage of significant
p-values is represented by the height of shading within the rectangle, the shading colour repre-
sents the direction of the effect (blue is a positive effect), and the hue represents the average
p-value among the significant p-values, with darker hues indicating lower p-values.
(TIF)
S18 Fig. Effects of RP race composition on prediction of age and health outcomes. The
study population represented here is the full WHAS data set using mixed, white-only, and
black-only RPs (also WHAS). The width of the rectangle represents the average effect size
among significant analyses, relative to the effect size of the rectangle in the leftmost column
(entire study population as its own RP). The percentage of significant p-values is represented
by the height of shading within the rectangle, the shading colour represents the direction of the
effect (blue is a positive effect), and the hue represents the average p-value among the signifi-
cant p-values, with darker hues indicating lower p-values.
(TIF)
S19 Fig. Effects of RP sex composition on prediction of age and health outcomes. The study
population represented here is the full InCHIANTI data set, varying the sex of the RP (also
InCHIANTI). The width of the rectangle represents the average effect size among significant
analyses, relative to the effect size of the rectangle in the leftmost column (entire study popula-
tion as its own RP). The percentage of significant p-values is represented by the height of shad-
ing within the rectangle, the shading colour represents the direction of the effect (blue is a
positive effect), and the hue represents the average p-value among the significant p-values, with
darker hues indicating lower p-values.
(TIF)
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